Sugi Predict

Sugi Predict / Compounds / SCHEMBL3584847

SCHEMBL3584847

SCHEMBL3584847

O=C(O)c1ccc(Cn2cccn2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.70
▸ HDAC6 Q9UBN7 1/20 0.70
▸ HTT P42858 1/20 0.70
▸ HSD17B10 Q99714 1/20 0.56
▸ MAPT P10636 4/20 0.54
▸ GAA P10253 3/20 0.54
▸ NOS3 P29474 1/20 0.52
▸ NOS1 P29475 1/20 0.52
▸ CA12 O43570 1/20 0.52
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ TDP1 Q9NUW8 2/20 0.50
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ TSHR P16473 1/20 0.49
▸ HRH3 Q9Y5N1 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17303471 0.88 HDAC1 (0.72) HDAC1HDAC6HTTMAPTGAA
SCHEMBL27273122 0.87 HDAC1 (0.70) HDAC1HDAC6HTTMAPTGAA
SCHEMBL15142218 0.86 HTT (0.62) HDAC1HDAC6HTTHSD17B10MAPT
SCHEMBL17221212 0.85 HDAC1 (0.68) HDAC1HDAC6HTTMAPTGAA
SCHEMBL4915929 0.85 HDAC1 (0.68) HDAC1HDAC6HTTMAPTGAA
SCHEMBL24663640 0.84 HDAC1 (0.67) HDAC1HDAC6HTTMAPTGAA
SCHEMBL28841023 0.84 HTT (0.55) HDAC1HDAC6HTTHSD17B10KMT2A
SCHEMBL7081878 0.83 HTT (0.75) HDAC1HDAC6HTTHSD17B10MAPT
SCHEMBL17221747 0.83 HDAC1 (0.61) HDAC1HDAC6HTTMAPTGAA
SCHEMBL30298601 0.83 HDAC1 (0.65) HDAC1HDAC6HTTMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 — — US disclosed
WO-2025068943-A1 KAT6 INHIBITORS BEIGENE SWITZERLAND GMBH (CH) 2025-04-03 — — WO disclosed
US-8541457-B2 Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2013-09-24 — — US disclosed
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2013-04-18 — — US disclosed
EP-2540296-A1 Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors Xenon Pharmaceuticals Inc. (CA) 2013-01-02 — — EP disclosed
WO-2010133544-A1 PIPERAZINE AND AMINOPYRROLIDINE COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC AG (DE) 2010-11-25 — — WO disclosed
WO-2010133544-A1 PIPERAZINE AND AMINOPYRROLIDINE COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC AG (DE) 2010-11-25 — — WO disclosed
CN-101778838-A Azacyclylbenzamide derivatives as histamine-3 antagonists WYETH CORP 2010-07-14 — — CN disclosed
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2010-06-17 — — US disclosed
EP-2155719-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS Wyeth LLC (US) 2010-02-24 — — EP disclosed
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-11-27 — — US disclosed
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-11-27 — — US disclosed
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-11-27 — — US disclosed
WO-2007130075-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-11-15 — — WO disclosed
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 — — US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 — — EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 — — US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 — — US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 — — US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 HDAC1 17/4885HDAC6 89/4885HTT 4800/4885
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, ACAT1 HDAC1 667/4885HDAC6 2058/4885HTT 1544/4885
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, ACAT1 HDAC1 661/4885HDAC6 2034/4885HTT 1527/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 HDAC1 51/4885HDAC6 264/4885HTT 4182/4885
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 HDAC1 11/4885HDAC6 8/4885HTT 69/4885
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS HRH4, HRH3, HRH2 HDAC1 482/4885HDAC6 425/4885HTT 867/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 HDAC1 50/4885HDAC6 299/4885HTT 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.